Everyday Health on MSN
What is fixed-duration CLL treatment?
Fixed-duration CLL treatment is changing management options for the condition. Here’s what it is, how it works, its potential ...
KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but ...
In the biggest venture capital financing this week, clinical-stage radiopharmaceutical AdvanCell has closed a $315 million ...
Is there something to reduce leakage? Is there something in the blood-retinal barrier? Is there something that Ang2 or other ...
Funding will support continued development of Calpurbatug (TRL1068), a novel therapy being evaluated for prosthetic joint infections (PJI) REDWOOD CITY, Calif., July 16, 2026 /PRNewswire/ -- Trellis ...
Morning Overview on MSN
A drug hit its goal against an aggressive lymphoma in a late-stage trial
Patients with relapsed or refractory diffuse large B-cell lymphoma, one of the fastest-growing blood cancers, gained a new ...
One trial, SIGMA, will evaluate Grifols’ intravenous immunoglobulin (Ig) GAMUNEX®-C (immune globulin injection [human], 10% caprylate chromatography purified) plus standard medical treatment in ...
Dozens of research teams around the world are working to halt, treat and even prevent Alzheimer's disease, which silently ...
The antibody uses a dual mechanism of action and works to block the interaction between TSLP and its receptor.
Cases of alpha-gal syndrome, a red meat allergy that comes from a tick bite, are climbing fast. But why does it only develop ...
Eleven new molecular drug targets receive approval in 2025, expanding treatment options for rare diseases, cancer, and infectious diseases.
Background Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers due to its aggressive biology and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results